Press "Enter" to skip to content

Eli Lilly’s Next-gen GLP-1 to Target Sugar Levels In Diabetic Patients

The three doses of tirzepatide are found to lower the blood sugar levels and the increased weight of the body in adults suffering from Type 2 diabetes. The tirzepatide has been effective in many Patients who had not even tried a diabetes-specific treatment.The tirzepatide has two mechanisms that had formed one drug. It has added GIP to GLP-1. The combination is used to prepare many diabetic drugs like Novo Nordisk’s semaglutide.

The Novo Nordisk’s semaglutide is sold under the name of Ozempic and Rybelsus in the U.S market. The medication developed by Lilly, dulaglutide, is sold by Lilly in the U.S market by the name Trulicity.Lilly believed that both would be more effective, and the clinical trials have shown a positive sign. Patients taking the dose for 40 continuous weeks lose an average of 11% of body weight.

Also, the blood sugar levels in these have dropped by 2.07%. Many of the Patients who were administered high doses saw that their blood sugar levels fell below 5.7%.

The top dose has dramatically reduced blood sugar levels. The other two doses that were 5 mg and 10 mg, also have been effective in lowering the blood sugar levels. The company revealed the results of the who continued to take the drug. It also announced the results of the Patients who took at least one dose of tirzepatide.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *